Abstract
Recent studies have highlighted a group of 4-repeat (4R) tauopathies that are characterised neuropathologically by widespread, globular glial inclusions (GGIs). Tau immunohistochemistry reveals 4R immunoreactive globular oligodendroglial and astrocytic inclusions and the latter are predominantly negative for Gallyas silver staining. These cases are associated with a range of clinical presentations, which correlate with the severity and distribution of underlying tau pathology and neurodegeneration. Their heterogeneous clinicopathological features combined with their rarity and under-recognition have led to cases characterised by GGIs being described in the literature using various and redundant terminologies. In this report, a group of neuropathologists form a consensus on the terminology and classification of cases with GGIs. After studying microscopic images from previously reported cases with suspected GGIs (n = 22), this panel of neuropathologists with extensive experience in the diagnosis of neurodegenerative diseases and a documented record of previous experience with at least one case with GGIs, agreed that (1) GGIs were present in all the cases reviewed; (2) the morphology of globular astrocytic inclusions was different to tufted astrocytes and finally that (3) the cases represented a number of different neuropathological subtypes. They also agreed that the different morphological subtypes are likely to be part of a spectrum of a distinct disease entity, for which they recommend that the overarching term globular glial tauopathy (GGT) should be used. Type I cases typically present with frontotemporal dementia, which correlates with the fronto-temporal distribution of pathology. Type II cases are characterised by pyramidal features reflecting motor cortex involvement and corticospinal tract degeneration. Type III cases can present with a combination of frontotemporal dementia and motor neuron disease with fronto-temporal cortex, motor cortex and corticospinal tract being severely affected. Extrapyramidal features can be present in Type II and III cases and significant degeneration of the white matter is a feature of all GGT subtypes. Improved detection and classification will be necessary for the establishment of neuropathological and clinical diagnostic research criteria in the future.
Similar content being viewed by others
References
Ahmed Z, Doherty KM, Silveira-Moriyama L et al (2011) Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. Acta Neuropathol 122:415–428
Berry RW, Quinn B, Johnson N, Cochran EJ, Ghoshal N, Binder LI (2001) Pathological glial tau accumulations in neurodegenerative disease: review and case report. Neurochem Int 39:469–479
Bigio EH, Lipton AM, Yen SH et al (2001) Frontal lobe dementia with novel tauopathy: sporadic multiple system tauopathy with dementia. J Neuropathol Exp Neurol 60:328–341
Cairns NJ, Atkinson PF, Hanger DP, Anderton BH, Daniel SE, Lantos PL (1997) Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer’s disease. Neurosci Lett 230:49–52
Dickson DW, Hauw JJ, Agid Y, Litvan I (2011) Progressive supranuclear palsy and corticobasal degeneration. In: Dickson DW, Weller RO (eds) Neurodegeneration: The molecular pathology of dementia and movement disorders, 2nd edn. Wiley-Blackwell, Chichester, West Sussex, pp 135–155
Ferrer I, Hernandez I, Boada M et al (2003) Primary progressive aphasia as the initial manifestation of corticobasal degeneration and unusual tauopathies. Acta Neuropathol 106:419–435
Fu YJ, Nishihira Y, Kuroda S et al (2010) Sporadic four-repeat tauopathy with frontotemporal lobar degeneration, Parkinsonism, and motor neuron disease: a distinct clinicopathological and biochemical disease entity. Acta Neuropathol 120:21–32
Gallyas F (1971) Silver staining of Alzheimer’s neurofibrillary changes by means of physical development. Acta morphol Acad Sci Hung 19:1–8
Ghetti B, Wszolek EK, Boeve BF, Spina S, Goedert M (2011) Frontotemporal dementia and Parkinsonism linked to chromosome 17. In: Dickson DW, Weller RO (eds) Neurodegeneration: the molecular pathology of dementia and movement disorders. Wiley-Blackwell, Chichester, West Sussex, pp 110–134
Giaccone G, Marcon G, Mangieri M et al (2008) Atypical tauopathy with massive involvement of the white matter. Neuropathol Appl Neurobiol 34:468–472
Hayashi S, Toyoshima Y, Hasegawa M et al (2002) Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation. Ann Neurol 51:525–530
Josephs KA, Katsuse O, Beccano-Kelly DA et al (2006) Atypical progressive supranuclear palsy with corticospinal tract degeneration. J Neuropathol Exp Neurol 65:396–405
Kovacs GG, Majtenyi K, Spina S et al (2008) White matter tauopathy with globular glial inclusions: a distinct sporadic frontotemporal lobar degeneration. J Neuropathol Exp Neurol 67:963–975
Lashley T, Rohrer JD, Bandopadhyay R et al (2011) A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain 134:2548–2564
Mackenzie IR (2007) The neuropathology of FTD associated With ALS. Alzheimer Dis Assoc Disord 21:S44–S49
Mackenzie IR, Neumann M, Bigio EH et al (2009) Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 117:15–18
Mackenzie IR, Neumann M, Bigio EH et al (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119:1–4
Molina JA, Probst A, Villanueva C et al (1998) Primary progressive aphasia with glial cytoplasmic inclusions. Eur Neurol 40:71–77
Ozawa T, Paviour D, Quinn NP et al (2004) The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 127:2657–2671
Piao YS, Tan CF, Iwanaga K et al (2005) Sporadic four-repeat tauopathy with frontotemporal degeneration, parkinsonism and motor neuron disease. Acta Neuropathol 110:600–609
Powers JM, Byrne NP, Ito M et al (2003) A novel leukoencephalopathy associated with tau deposits primarily in white matter glia. Acta Neuropathol 106:181–187
Spillantini MG, Goedert M, Crowther RA, Murrell JR, Farlow MR, Ghetti B (1997) Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci USA 94:4113–4118
Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA 95:7737–7741
Spina S, Farlow MR, Unverzagt FW et al (2008) The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain 131:72–89
Tolnay M, Braak H (2011) Argyrophilic grain disease. In: Dickson DW, Weller RO (eds) Neurodegeneration: the molecular pathology of dementia and movement disorders, 2nd edn. Wiley-Blackwell, Chichester, West Sussex, pp 165–170
Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG (2008) Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol 64:239–246
Wray S, Saxton M, Anderton BH, Hanger DP (2008) Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats. J Neurochem 105:2343–2352
Acknowledgments
Grant supports: BG—PHS P30 AG010133; CLW and KJH—NIH P30 AG12300, and CLW—Winspear Family Center for Research on the Neuropathology of Alzheimer Disease, and McCune Foundation; EHB—AG13854; GG—Italian Ministry of Health; HT—Research Committee for CNS Degenerative Diseases, the Ministry of Health, Labour and Welfare, Japan; KAJ—NIH R01 AG37491; GGK-DEVELAGE (FP7/2007–2013, N° 278486); TR and JLH—the Multiple System Atrophy Trust, The Alzheimer’s Research Trust and Parkinson’s UK and JLH—the Reta Lila Weston Institute for Neurological Studies. The Queen Square Brain Bank is supported by the Reta Lila Weston Institute for Neurological Studies and the PSP (Europe) Association. Part of this work was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centres funding scheme and, in part, funded/supported by the National Institute for Health Research (NIHR) Biomedical Research Unit in Dementia based at University College London Hospitals (UCLH), University College London (UCL). Zeshan Ahmed is currently a post-doctoral research fellow at Eli Lilly and Company.
Author information
Authors and Affiliations
Corresponding author
Additional information
Z. Ahmed and G. G. Kovacs contributed equally to this article.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ahmed, Z., Bigio, E.H., Budka, H. et al. Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathol 126, 537–544 (2013). https://doi.org/10.1007/s00401-013-1171-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00401-013-1171-0